TC BioPharm Secures CryoTC Trademark For Cell Freezing Process

TC Biopharm Ltd (NASDAQ:TCBP) has registered the U.K. trademark CryoTC for its proprietary process for freezing and thawing its lead oncology product, OmnImmune.

• CryoTR is TC BioPharm's unique cryopreservation process, which is performed in a controlled rate freezer using an optimized protocol. 
• OmnImmune is an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells. 
• OmnImmune comprises GDT cells sourced from healthy donors, activated, and expanded in large numbers before being purified, formulated, and cryopreserved for subsequent thawing and infusion into patients. 
• Last month, the FDA granted Orphan Drug designation to TC Biopharm OmnImmune for use in acute myeloid leukemia. 
• The company plans to initiate Phase 2/3 trial enrollment in Q1 of 2022 in the U.K., expanding into the U.S. in 2022.
• Price Action: TCBP shares are down 3.23% at $1.50 on the last check Wednesday.